Table 1 Core Gene Pathway Alterations and Association with Tumor Differentiation in KRASmut PDAC
Mutated pathway in KRASmut PDAC | Moderate and well differentiated n=260 | P | Poor differentiated n=284 | P |
|---|---|---|---|---|
TP53 | ||||
 Missense | 94 (36.1%) | 1 | 144 (50.7%) | 0.001†|
 Truncating | 53 (20.4%) | 1 | 53 (18.7%) | 0.612†|
 Others* | 2 (0.8%) | 1 | 11 (3.9%) | 0.018†|
 Overall mutated | 149 (57.3%) | 1 | 208 (73.3%) | <0.001†|
Cell cycle | ||||
 CDKN2A | 37 (14.2%) | 1 | 52 (18.3%) | 0.199†|
 Overall mutated | 42 (16.2%) | 1 | 58 (20.4%) | 0.199†|
 TGFb | 62 (23.8%) | 1 | 60 (21.1%) | 0.447†|
2-3 mutated pathways** | 63 (24.2%) | 1 | 91 (32.0%) | 0.043†|
Trithorax | 52 (20.0%) | 1 | 70 (24.6%) | 0.194†|
HRD | 39 (15.0%) | 1 | 46 (16.2%) | 0.701†|
MMRD | 6 (2.3%) | 1 | 6 (2.1%) | 0.877†|
RNA processing | 11 (4.2%) | 1 | 8 (2.8%) | 0.370†|
PI3K-Akt | 3 (1.2%) | 1 | 3 (1.1%) | 1.000‡ |
WNT | 26 (10.0%) | 1 | 22 (7.7%) | 0.355†|
NOTCH | 10 (3.8%) | 1 | 10 (3.5%) | 0.841†|
Hedgehog | 7 (2.7%) | 1 | 7 (2.5%) | 0.867†|
DNA modification | 6 (2.3%) | 1 | 11 (3.9%) | 0.295†|